135 related articles for article (PubMed ID: 38402087)
1. Sub-region based radiomics analysis for prediction of isocitrate dehydrogenase and telomerase reverse transcriptase promoter mutations in diffuse gliomas.
Zhang H; Ouyang Y; Zhang H; Zhang Y; Su R; Zhou B; Yang W; Lei Y; Huang B
Clin Radiol; 2024 May; 79(5):e682-e691. PubMed ID: 38402087
[TBL] [Abstract][Full Text] [Related]
2. Noninvasive prediction of IDH mutation status in gliomas using preoperative multiparametric MRI radiomics nomogram: A mutlicenter study.
Lu J; Xu W; Chen X; Wang T; Li H
Magn Reson Imaging; 2023 Dec; 104():72-79. PubMed ID: 37778708
[TBL] [Abstract][Full Text] [Related]
3. A radiomics-based nomogram may be useful for predicting telomerase reverse transcriptase promoter mutation status in adult glioblastoma.
Li Y; Chen L; Huang L; Li X; Huang Q; Tang L; Huang Z; Zhu L; Li T
Brain Behav; 2024 May; 14(5):e3528. PubMed ID: 38798094
[TBL] [Abstract][Full Text] [Related]
4. Enhancing predictability of IDH mutation status in glioma patients at initial diagnosis: a comparative analysis of radiomics from MRI, [
Kaiser L; Quach S; Zounek AJ; Wiestler B; Zatcepin A; Holzgreve A; Bollenbacher A; Bartos LM; Ruf VC; Böning G; Thon N; Herms J; Riemenschneider MJ; Stöcklein S; Brendel M; Rupprecht R; Tonn JC; Bartenstein P; von Baumgarten L; Ziegler S; Albert NL
Eur J Nucl Med Mol Imaging; 2024 Jul; 51(8):2371-2381. PubMed ID: 38396261
[TBL] [Abstract][Full Text] [Related]
5. Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas.
Zhang B; Chang K; Ramkissoon S; Tanguturi S; Bi WL; Reardon DA; Ligon KL; Alexander BM; Wen PY; Huang RY
Neuro Oncol; 2017 Jan; 19(1):109-117. PubMed ID: 27353503
[TBL] [Abstract][Full Text] [Related]
6. Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma.
Kim M; Jung SY; Park JE; Jo Y; Park SY; Nam SJ; Kim JH; Kim HS
Eur Radiol; 2020 Apr; 30(4):2142-2151. PubMed ID: 31828414
[TBL] [Abstract][Full Text] [Related]
7. Amide proton transfer-weighted imaging and derived radiomics in the classification of adult-type diffuse gliomas.
Wu M; Jiang T; Guo M; Duan Y; Zhuo Z; Weng J; Xie C; Sun J; Li J; Cheng D; Liu X; Du J; Zhang X; Zhang Y; Liu Y
Eur Radiol; 2024 May; 34(5):2986-2996. PubMed ID: 37855851
[TBL] [Abstract][Full Text] [Related]
8. Deep Learning Radiomics for the Assessment of Telomerase Reverse Transcriptase Promoter Mutation Status in Patients With Glioblastoma Using Multiparametric MRI.
Zhang H; Zhang H; Zhang Y; Zhou B; Wu L; Lei Y; Huang B
J Magn Reson Imaging; 2023 Nov; 58(5):1441-1451. PubMed ID: 36896953
[TBL] [Abstract][Full Text] [Related]
9. Predicting Isocitrate Dehydrogenase (IDH) Mutation Status in Gliomas Using Multiparameter MRI Radiomics Features.
Peng H; Huo J; Li B; Cui Y; Zhang H; Zhang L; Ma L
J Magn Reson Imaging; 2021 May; 53(5):1399-1407. PubMed ID: 33179832
[TBL] [Abstract][Full Text] [Related]
10. Using radiomics based on multicenter magnetic resonance images to predict isocitrate dehydrogenase mutation status of gliomas.
Liu Y; Zheng Z; Wang Z; Qian X; Yao Z; Cheng C; Zhou Z; Gao F; Dai Y
Quant Imaging Med Surg; 2023 Apr; 13(4):2143-2155. PubMed ID: 37064376
[TBL] [Abstract][Full Text] [Related]
11. Predicting isocitrate dehydrogenase status among adult patients with diffuse glioma using patient characteristics, radiomic features, and magnetic resonance imaging: Multi-modal analysis by variable vision transformer.
Usuzaki T; Inamori R; Shizukuishi T; Morishita Y; Takagi H; Ishikuro M; Obara T; Takase K
Magn Reson Imaging; 2024 Sep; 111():266-276. PubMed ID: 38815636
[TBL] [Abstract][Full Text] [Related]
12. Generative AI in glioma: Ensuring diversity in training image phenotypes to improve diagnostic performance for IDH mutation prediction.
Moon HH; Jeong J; Park JE; Kim N; Choi C; Kim YH; Song SW; Hong CK; Kim JH; Kim HS
Neuro Oncol; 2024 Jun; 26(6):1124-1135. PubMed ID: 38253989
[TBL] [Abstract][Full Text] [Related]
13. Multiparametric MRI-based fusion radiomics for predicting telomerase reverse transcriptase (TERT) promoter mutations and progression-free survival in glioblastoma: a multicentre study.
Zhang H; Zhang H; Zhang Y; Zhou B; Wu L; Yang W; Lei Y; Huang B
Neuroradiology; 2024 Jan; 66(1):81-92. PubMed ID: 37978079
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of clinical-radiomics analysis for preoperative prediction of IDH mutation status and WHO grade in diffuse gliomas: a consecutive L-[methyl-11C] methionine cohort study with two PET scanners.
Zhou W; Wen J; Huang Q; Zeng Y; Zhou Z; Zhu Y; Chen L; Guan Y; Xie F; Zhuang D; Hua T
Eur J Nucl Med Mol Imaging; 2024 Apr; 51(5):1423-1435. PubMed ID: 38110710
[TBL] [Abstract][Full Text] [Related]
15. The efficacy of using a multiparametric magnetic resonance imaging-based radiomics model to distinguish glioma recurrence from pseudoprogression.
Fu FX; Cai QL; Li G; Wu XJ; Hong L; Chen WS
Magn Reson Imaging; 2024 Sep; 111():168-178. PubMed ID: 38729227
[TBL] [Abstract][Full Text] [Related]
16. Establishment of a Prediction Model Based on Preoperative MRI Radiomics for Diffuse Astrocytic Glioma, IDH-Wildtype, with Molecular Features of Glioblastoma.
Du P; Wu X; Liu X; Chen J; Cao A; Geng D
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894461
[TBL] [Abstract][Full Text] [Related]
17. Peritumoral Radiomics for Identification of Telomerase Reverse Transcriptase Promoter Mutation in Patients With Glioblastoma Based on Preoperative MRI.
Zhang H; Zhou B; Zhang H; Zhang Y; Lei Y; Huang B
Can Assoc Radiol J; 2024 Feb; 75(1):143-152. PubMed ID: 37552107
[No Abstract] [Full Text] [Related]
18. A radiomics feature-based nomogram to predict telomerase reverse transcriptase promoter mutation status and the prognosis of lower-grade gliomas.
Lu J; Li X; Li H
Clin Radiol; 2022 Aug; 77(8):e560-e567. PubMed ID: 35595562
[TBL] [Abstract][Full Text] [Related]
19. Integrated CT Radiomics Features Could Enhance the Efficacy of
Zhou W; Huang Q; Wen J; Li M; Zhu Y; Liu Y; Dai Y; Guan Y; Zhou Z; Hua T
Front Oncol; 2021; 11():772703. PubMed ID: 34869011
[TBL] [Abstract][Full Text] [Related]
20. Adding radiomics to the 2021 WHO updates may improve prognostic prediction for current IDH-wildtype histological lower-grade gliomas with known EGFR amplification and TERT promoter mutation status.
Park YW; Kim S; Park CJ; Ahn SS; Han K; Kang SG; Chang JH; Kim SH; Lee SK
Eur Radiol; 2022 Dec; 32(12):8089-8098. PubMed ID: 35763095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
